[go: up one dir, main page]

DK3354665T3 - Modificerede alginater til celleindkapsling og celleterapi - Google Patents

Modificerede alginater til celleindkapsling og celleterapi Download PDF

Info

Publication number
DK3354665T3
DK3354665T3 DK18162427.1T DK18162427T DK3354665T3 DK 3354665 T3 DK3354665 T3 DK 3354665T3 DK 18162427 T DK18162427 T DK 18162427T DK 3354665 T3 DK3354665 T3 DK 3354665T3
Authority
DK
Denmark
Prior art keywords
cell
enclosure
modified alginates
therapy
cell therapy
Prior art date
Application number
DK18162427.1T
Other languages
English (en)
Other versions
DK3354665T5 (da
Inventor
Kaitlin M Bratlie
Robert S Langer
Minglin Ma
Daniel G Anderson
Arturo J Vegas
Original Assignee
Massachusetts Inst Technology
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Childrens Medical Ct Corp filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK3354665T3 publication Critical patent/DK3354665T3/da
Publication of DK3354665T5 publication Critical patent/DK3354665T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18162427.1T 2011-06-02 2012-06-04 Modificerede alginater til celleindkapsling og celleterapi DK3354665T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492705P 2011-06-02 2011-06-02
EP12728887.6A EP2714747B1 (en) 2011-06-02 2012-06-04 Modified alginates for cell encapsulation and cell therapy

Publications (2)

Publication Number Publication Date
DK3354665T3 true DK3354665T3 (da) 2022-04-25
DK3354665T5 DK3354665T5 (da) 2022-09-19

Family

ID=46321466

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18162427.1T DK3354665T5 (da) 2011-06-02 2012-06-04 Modificerede alginater til celleindkapsling og celleterapi

Country Status (6)

Country Link
US (6) US9422373B2 (da)
EP (3) EP3354665B9 (da)
CA (1) CA2837558C (da)
DK (1) DK3354665T5 (da)
ES (1) ES2912545T3 (da)
WO (1) WO2012167223A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240157103A (ko) * 2014-08-01 2024-10-31 메사추세츠 인스티튜트 오브 테크놀로지 항-섬유 물질 및 응용을 위한 변형된 알기네이트
JP2018507916A (ja) * 2015-03-11 2018-03-22 ベフファル アタ エクソソーム送達技術
KR102558416B1 (ko) * 2015-11-01 2023-07-24 메사추세츠 인스티튜트 오브 테크놀로지 개선된 특성을 가진 물질
RU2018120104A (ru) 2015-11-01 2019-12-02 Массачусетс Инститьют Оф Текнолоджи Модифицированные альгинаты в качестве противофиброзных материалов и их применения
EP3403098B1 (en) 2016-01-12 2021-09-22 BioAtla, Inc. Diagnostics using conditionally active antibodies
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
US9999640B2 (en) 2016-02-02 2018-06-19 University Of Dammam Microencapsulated probiotic bacteria
US10046985B2 (en) 2016-02-11 2018-08-14 King Fahd University Of Petroleum And Minerals Method for removing cationic dyes from an aqueous solution using an adsorbent
WO2017165389A2 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Alginate hydrogel compositions
BR112018075841A2 (pt) 2016-06-13 2019-03-19 Massachusetts Institute Of Technology polímero biocompatível, hidrogel, dispositivo, biomaterial e método de preparação do hidrogel
EP3512500A1 (en) 2016-09-14 2019-07-24 Ecole Polytechnique Federale de Lausanne (EPFL) Hydrogels based on functionalized polysaccharides
EP3295933A1 (en) 2016-09-14 2018-03-21 Ecole Polytechnique Federale De Lausanne (Epfl) Hydrogels based on functionalized polysaccharides
EA201991452A1 (ru) 2016-12-13 2020-01-16 Милленниум Фармасьютикалз, Инк. Конформное покрытие биологических поверхностей
CN118108677A (zh) * 2017-01-27 2024-05-31 康奈尔大学 两性离子修饰的聚合物和水凝胶
WO2018232027A1 (en) 2017-06-13 2018-12-20 Massachusetts Institute Of Technology Biocompatible microfabricated devices for transplanting cells
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019090309A1 (en) 2017-11-06 2019-05-09 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants
US12162994B2 (en) 2018-03-02 2024-12-10 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
KR20210004969A (ko) 2018-03-02 2021-01-13 시질론 테라퓨틱스, 인크. 비섬유성 화합물, 디바이스 및 그의 용도
JP2021515581A (ja) * 2018-03-16 2021-06-24 ニューテック・ベンチャーズ 細胞増殖システム
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
CN112236457B (zh) 2018-06-14 2023-08-29 持田制药株式会社 新型交联海藻酸
US20210353781A1 (en) * 2018-09-21 2021-11-18 Massachusetts Institute Of Technology Surface-modified cells, methods of making and using
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
EP3924008B1 (en) 2019-02-15 2025-04-09 William Marsh Rice University Vascularizing devices and methods for implanted diagnostics and therapeutics
JP7236533B2 (ja) 2019-04-09 2023-03-09 富士フイルム株式会社 マイクロカプセルの製造方法およびコート液
WO2021039610A1 (ja) 2019-08-23 2021-03-04 富士フイルム株式会社 ミクロカプセルと細胞構造体とを含む組成物
US12306081B2 (en) 2019-12-04 2025-05-20 Sigilon Therapeutics, Inc. Apparatuses and methods for formation of particles
WO2021202945A1 (en) * 2020-04-02 2021-10-07 Cornell University Nanofiber-enabled encapsulation devices and uses thereof
EP3940072A1 (en) * 2020-07-13 2022-01-19 Biomillenia SAS Alginate beads and production thereof
US20220089537A1 (en) 2020-09-18 2022-03-24 Massachusetts Institute Of Technology High-throughput method to rapidly add chemical moieties to a small molecule library
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
EP4531942A1 (en) 2022-06-03 2025-04-09 Flagship Pioneering Innovations VI, LLC Compositions and methods
AU2023300165A1 (en) 2022-07-01 2025-02-13 Sigilon Therapeutics, Inc. Covalently photocrosslinked polysaccharides and methods of use thereof
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024191428A1 (en) 2023-03-14 2024-09-19 Sigilon Therapeutics, Inc. Hydrogel capsules comprising covalently photocrosslinked polysaccharides and islet cells
WO2025117331A1 (en) 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB676618A (en) * 1947-09-12 1952-07-30 Kelco Co Alkylene glycol esters of alginic acid
GB768309A (en) * 1954-03-27 1957-02-13 Henkel & Cie Gmbh Process for the production of amides of alginic acid
US2860130A (en) * 1954-11-01 1958-11-11 Kelco Co Methyl alginate
US2881161A (en) * 1955-03-25 1959-04-07 Henkel & Cie Gmbh Amides of alginic acid
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
NO845059L (no) 1984-12-17 1986-06-18 Sintef Inst For Marin Biokjemi Fremgangsmaate for fremstilling av alginater med endrede fysikalske egenskaper samt anvendelse av disse alginater.
IT1203814B (it) 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
WO1989008446A1 (fr) * 1988-03-09 1989-09-21 Snow Brand Milk Products Co., Ltd. Preparation a liberation freinee preparee grace a l'utilisation d'acide alginique
JP2643669B2 (ja) 1990-12-28 1997-08-20 共成製薬株式会社 アルギン含有食品
US5876452A (en) 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
FR2699545B1 (fr) 1992-12-18 1995-01-27 Oreal Agent gélifiant résultant de l'association d'un chitosane et d'un alginate d'alkyle ou d'hydroxyalkyle et son utilisation dans la préparation de compositions cosmétiques et pharmaceutiques.
EP2025353A2 (en) 1993-04-30 2009-02-18 Massachusetts Institute of Technology Injectable polysaccharide-cell compositions
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6171232B1 (en) 1997-06-26 2001-01-09 Cordis Corporation Method for targeting in vivo nitric oxide release
US6440940B1 (en) 1997-12-18 2002-08-27 Peter J. Doyle Bioresorbable alginate derivatives
US6159531A (en) 1999-08-30 2000-12-12 Cardiovasc, Inc. Coating having biological activity and medical implant having surface carrying the same and method
US6932894B2 (en) 2001-05-15 2005-08-23 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
US6977138B2 (en) 2001-07-24 2005-12-20 Massachusetts Institute Of Technology Reactive polymer coatings
US20040043052A1 (en) 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
US7008476B2 (en) 2003-06-11 2006-03-07 Az Electronic Materials Usa Corp. Modified alginic acid of alginic acid derivatives and thermosetting anti-reflective compositions thereof
US7329531B2 (en) 2003-12-12 2008-02-12 Scimed Life Systems, Inc. Blood-tight implantable textile material and method of making
CN1897890B (zh) 2003-12-23 2012-01-25 Fmc生物聚合物联合股份有限公司 用藻酸盐基质控制细胞生长
ITMI20041373A1 (it) * 2004-07-09 2004-10-09 Lima Lto S P A N-metil-ammidi di carbossimetilcellulosa acido alginico o carbossimetalamido
EP1817346A1 (en) 2004-11-12 2007-08-15 FMC Biopolymer AS Modified alginates, methods of production and use
ATE533791T1 (de) * 2005-09-27 2011-12-15 Univ Grenoble 1 Mit einer polymerisierbaren gruppierung funktionalisiertes hydrogel und anwendungen davon als biosensoren oder bioreaktoren
DE102005049833A1 (de) * 2005-10-14 2007-04-19 Beiersdorf Ag Hydrophob modifizierte Alginate
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
US8211361B2 (en) 2007-03-26 2012-07-03 Board Of Regents, The University Of Texas System N-halamine-based rechargeable biofilm-controlling tubular devices, method of making and using
US7515808B2 (en) 2007-06-01 2009-04-07 Alcatel-Lucent Usa Inc. Thermally stabilized waveguides
KR20100063744A (ko) 2007-08-28 2010-06-11 에프엠씨 코포레이션 지연된 자가-겔화 알기네이트 시스템 및 이의 용도
US7998524B2 (en) 2007-12-10 2011-08-16 Abbott Cardiovascular Systems Inc. Methods to improve adhesion of polymer coatings over stents
EP2127689A1 (en) 2008-05-27 2009-12-02 RevisiOs B.V. i.o. Novel homogenous osteoinductive nanocomposites
CN101565469B (zh) * 2008-10-28 2011-05-11 中国海洋大学 酰胺接枝的海藻酸钠纳米材料及其制备方法与应用
CA2745307A1 (en) 2008-12-12 2010-06-17 University Of Massachusetts Polyesters with grafted zwitterions
EP2393526B1 (en) 2009-02-09 2014-04-09 St. Jude Medical, Inc. Enhancing biocompatibility of a medical device
US9555154B2 (en) 2009-02-21 2017-01-31 Covidien Lp Medical devices having activated surfaces
JP5743287B2 (ja) 2009-10-16 2015-07-01 ディーエスエム アイピー アセッツ ビー．ブイ． ビス−（アルファ−アミノ−ジオール−ジエステル）を含有するポリエステルアミドを含むコーティング
EP4245370A3 (en) 2010-07-12 2023-11-29 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
US20120083767A1 (en) 2010-10-01 2012-04-05 The Johns Hopkins University Implantable bioreactor for delivery of paracrine factors
JP5963130B2 (ja) 2012-02-16 2016-08-03 学校法人同志社 生体組織補強材料キット及び生体組織補強材料

Also Published As

Publication number Publication date
WO2012167223A1 (en) 2012-12-06
CA2837558C (en) 2018-11-20
DK3354665T5 (da) 2022-09-19
ES2912545T3 (es) 2022-05-26
US20170239190A1 (en) 2017-08-24
US10292936B2 (en) 2019-05-21
US9422373B2 (en) 2016-08-23
CA2837558A1 (en) 2012-12-06
US20190262272A1 (en) 2019-08-29
EP3354665A1 (en) 2018-08-01
EP3354665B9 (en) 2022-08-03
US20210186886A1 (en) 2021-06-24
US20120308650A1 (en) 2012-12-06
US10285949B2 (en) 2019-05-14
US10842753B2 (en) 2020-11-24
EP2714747A1 (en) 2014-04-09
EP4083074A1 (en) 2022-11-02
HK1259279A1 (en) 2019-11-29
EP2714747B1 (en) 2020-08-05
US11337930B2 (en) 2022-05-24
US20160324793A1 (en) 2016-11-10
US20230130084A1 (en) 2023-04-27
EP3354665B1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
DK3354665T3 (da) Modificerede alginater til celleindkapsling og celleterapi
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
DK2950535T3 (da) Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK3257943T3 (da) Fremgangsmåder og vektorer til celleimmortalisering
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK3578201T3 (da) Fremgangsmåder og sammensætninger til naturlige dræberceller
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK3689878T3 (da) 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer
DK3202760T3 (da) Pegylerede lipider og deres anvendelse til lægemiddelfremføring
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
IL230467B (en) Compositions and methods for modulating metabolic pathways
DK2855736T3 (da) Elektrolysator og energisystem
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK2705143T3 (da) Protein-induceret pluripotent celleteknologi og anvendelse deraf
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
DK2699562T3 (da) Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
CO7020866A2 (es) Péptidos terapéuticos
DK2758655T3 (da) Systemer og fremgangsmåder til forbedrede vandrotorer
DK2666475T3 (da) Terapeutisk middel til skaldethed
PL2771037T3 (pl) Środki terapeutyczne i ich zastosowania
DK2785683T3 (da) Inkt-cellemodulatorer og fremgangsmåder til anvendelse heraf